Find a Doctor

Return to Physician Search

Physician Profile

Edward A. Faber, DO, MS

Edward A. Faber Jr., D.O., MS

"The doctors and researchers at OHC are leaders in clinical trials and ongoing research," says Dr. Faber. "They are a compassionate and dedicated group, and everyone works together to provide the latest treatments and world-class patient care. I'm excited to be a part of that."
Learn More.


Blood & Marrow Transplants
Medical Oncology




or call


Malignant hematology (blood cancers): acute leukemias, chronic leukemias, Hodgkin’s and non-Hodgkin’s lymphomas, myeloma, myelodysplastic syndromes, aplastic anemia

Benign hematology (non blood cancers):  polycythemia vera, essential thrombocythemia, myelofribrosis, amyloidosis and acquired or inherited clotting and bleeding disorders

Blood and marrow transplantation: autologous and allogeneic bone marrow and peripheral blood stem cell transplants


Bone and marrow transplants (BMT)
Cancer clinical trials and research


Biking, golfing, hockey, and aspirations to become a professional chef.


Lake Erie College of Osteopathic Medicine, Erie, PA


University of Pittsburgh Medical Center (UPMC) – Mercy Hospital


University of Pittsburgh Medical Center (UPMC) – Mercy Hospital


Michigan State University, Hematology/Oncology


Penn State University, Behrend College, Certificate in Healthcare Management, Erie, PA
Duquesne University, Pittsburgh, Master of Science in Genetics and Molecular Biology
Allegheny College, Meadville, PA, BS in Biology and Chemistry


American Board of Internal Medicine, Internal Medicine
American Board of Internal Medicine, Medical Oncology
American Board of Internal Medicine, Hematology


American College of Physicians
American Medical Association
American Society of Hematology
American Society of Bone Marrow Transplant


ASBMT Clinical Research Training Course, July 2009 CSCR/MWAFMR Midwest Trainee Travel Award, April 2009 Managing Myeloma Scholarship, February 2009 First Place, ACP Scientific Meeting Abstract Presentation, “Positive Axillary Lymph Node and BRCA Gene Mutation in DCIS,” September 2007 Resident of the Year, University of Pittsburgh-Mercy Hospital, May 2006

Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber Jr EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockert-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F. Multiple Myeloma. J Natl Compr Canc Netw. 2011 Oct;9(10):146-83. PMID 21975914.

Faber Jr EA, Vose JM. The Role of Hematopoietic Cell Transplantation in Follicular Lymphoma. J Natl Compr Canc Netw. 2010 Mar;8(3):337-45. PMID: 20202463.

Faber Jr EA, Geyer S. Vena Cava Thrombosis and Fatal Pulmonary Death. Lab Medicine 33:553-555, 2002.

Andrews III DF, Faber E, Hawk H, Geyer S. Antisense Oligonucleotides to MDR1 Increase Adriamycin Susceptibility in Breast Cancer Cell Lines. Molecular Biology of Hematopoiesis. Ed. N.G. Abraham, et al. Plenum Press, NY, NY, 1996.


William BM, Raichlin Em Um JY, Morris MC, Miles CD, Gorggel GC, Faber Jr EA. Successful autologous stem cell transplant (ASCT) following a combined heart-kidney transplantation for AL amyloidosis. Poster. BMT Tandem Conference, February 2012.

Raje NS, Hohl RJ, Faber EA, Richardson PGG, Forero-Torres A, Schiller GJ, Cohen AD, Carpenter SP, Cronier D, Pashkevich M, Wooldridge J, Anderson KC. Phase 1 study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously-treated multiple myeloma. J Clin Oncol  (ASCO Annual Meeting Abstracts) 29: Suppl Abstr 8012. 2011.

Martin K, Reade C, Faber Jr EA. "Acute Severe Hypophosphatemia in IgG kappa Multiple Myeloma Treated with Lenalidomide". American College of Physicians, Nebraska Chapter Meeting. 2009.

Faber Jr EA, KA Schwartz, S Nagpal, et al. Hypercoagulation in Malignancy: Localized by Thromboelastography [TEG] to the Humoral Phase of Coagulation. CSCR/MWAFMR Chicago, IL 2009, Poster Number 75 and ISTH, Boston MA, Poster PP-WE-495. 2009.

S Nagpal, KA Schwartz, Faber Jr EA, et al.  The Role of Thromboelastography (TEG) in Predicting Thrombosis in Cancer Patients. Blood (ASH Annual Meeting Abstracts) 112: Abstract 5352, 2008.

Faber Jr EA, Alirah S, Tamkus D. Case Report: DCIS and BRCA, the Value of Sentinel Lymph Node Biopsy. ACP Scientific Meeting. September 2007.

Faber E, Andrews DF, Shadduck RK, Geyer S, Agha ME. Improved Efficiency of Growth Inhibition of BCR-ABL Positive Cells by Antisense Oligodeoxynucleotides - Cholesterol. ASH Conference. December 1995.

Andrews III DF, Geyer S, Hawk S, Faber E. Antisense Oligonucleotides to MDR1 Increase Adriamycin Susceptibility in Breast Cancer Cell Lines. 17th Annual San Antonio Breast Cancer Symposium. December 1994.

Like all OHC physicians, Dr. Faber has full access to the OHC clinical trial research program.

We encourage our patients to discuss all of their healthcare options — including Clinical Trial research programs — with their doctor.

The following are recent reviews provided by actual OHC patients:

He’s most excellent. Has my Multiple Myeloma in a maintained remission. And this new treatment for AML? What a game changer for those patients!
- Melody H.

When I started seeing him I was diagnosed with multi myloma and was is a lot of pain. As of now I am feeling so much better and doing much better. Come December I will be doing a stem cell transplant and I believe with Dr. Faber and his nursing staff by my side I will do great. Thanks to Dr. Faber I will be here for my family.
- Julie R.

He’s a excellent doctor. I am still alive.
- Dennis J.

That was main doctor at Jewish. He was my favorite out of all of them.
- Tammy A.

My oncologist…the absolute best! I was lucky to have found him and the Jewish Hospital team!
- Bob W.

Wonderful and caring doctor!
- Donna G.